Research programme: cancer therapeutics - Adocia

Drug Profile

Research programme: cancer therapeutics - Adocia

Alternative Names: Anticancer nanoparticles - Adocia; Cancer therapies - Adocia; DriveIn cancer therapeutics - Adocia; Ovarian cancer therapy - Adocia

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adocia
  • Class Proteins; Small molecules
  • Mechanism of Action DNA intercalators; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Ovarian cancer; Solid tumours

Most Recent Events

  • 27 Jul 2016 Discontinued - Preclinical for Solid tumours and for Ovarian Cancer in France (Parenteral) before July 2016 - Adocia focusing on the development of treatment for diabetes only
  • 01 Nov 2014 Preclinical trials in Solid tumours and Ovarian cancer in France (Parenteral)
  • 09 Dec 2013 Adocia receives development and commercialisation rights to the DriveIn® nanotechnology from CNRS, University Bordeaux I and SATT Aquitaine in the field of healthcare
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top